Exelixis to Host Investor Briefing to Discuss Data Presented at the European Society for Medical Oncology Virtual Congress 2020
September 14 2020 - 08:00AM
Business Wire
- Online event will be accessible at
www.exelixis.com -
Exelixis, Inc. (Nasdaq: EXEL) today announced it will host an
investor briefing to discuss data presented at the European Society
for Medical Oncology (ESMO) Virtual Congress 2020. The online-only
event will be held following the closing of the Congress’ sessions
on Saturday, September 19, 2020, beginning at 22:00 (10:00 p.m.)
CEST / 4:00 p.m. EDT / 1:00 p.m. PDT.
During the briefing, Exelixis management and invited guests from
the clinical community will discuss and provide context for the
cabozantinib clinical data presented at the Congress. Exelixis
previously announced that detailed results from CheckMate -9ER, the
phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) in
combination with Opdivo® (nivolumab) compared with sunitinib in
previously untreated patients with advanced or metastatic renal
cell carcinoma, will be presented during the Congress’ Presidential
Symposium I earlier in the day. The investor briefing will also
review data from COSMIC-021, the phase 1b trial of CABOMETYX in
combination with TECENTRIQ® (atezolizumab) in patients with locally
advanced or metastatic solid tumors, presented at the Congress.
To access the investor briefing, log onto www.exelixis.com and
proceed to the News & Events / Event Calendar page under the
Investors & Media heading. Please connect to the company’s
website at least 15 minutes prior to the event to ensure adequate
time for any software download that may be required to view the
webcast. After the event concludes, a replay will be available at
that same location for a minimum of one year.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in
model system genetics, we established a broad drug discovery and
development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in
need. Our discovery efforts have resulted in four commercially
available products, CABOMETYX® (cabozantinib), COMETRIQ®
(cabozantinib), COTELLIC® (cobimetinib) and MINNEBRO®
(esaxerenone), and we have entered into partnerships with leading
pharmaceutical companies to bring these important medicines to
patients worldwide. Supported by revenues from our marketed
products and collaborations, we are committed to prudently
reinvesting in our business to maximize the potential of our
pipeline. We are supplementing our existing therapeutic assets with
targeted business development activities and internal drug
discovery - all to deliver the next generation of Exelixis
medicines and help patients recover stronger and live longer.
Exelixis is a member of Standard & Poor’s (S&P) MidCap 400
index, which measures the performance of profitable mid-sized
companies. For more information about Exelixis, please visit
www.exelixis.com, follow @ExelixisInc on Twitter or like Exelixis,
Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX,
COMETRIQ and COTELLIC are registered U.S. trademarks. MINNEBRO is a
registered Japanese trademark.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200914005441/en/
Investors Contact: Varant Shirvanian Sr. Investor
Relations Manager Exelixis, Inc. 650-837-7917
vshirvanian@exelixis.com
Media Contact: Hal Mackins For Exelixis, Inc.
415-994-0040 hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Mar 2023 to Mar 2024